iTeos Therapeutics Inc. (ITOS)
7.71
-0.09 (-1.15%)
At close: Jan 14, 2025, 3:59 PM
7.66
-0.58%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 7.3 |
| Market Cap | 281.49M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.14 |
| PE Ratio (ttm) | -2.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.44 |
| Volume | 288,981 |
| Avg. Volume (20D) | 550,183 |
| Open | 7.84 |
| Previous Close | 7.80 |
| Day's Range | 7.63 - 7.92 |
| 52-Week Range | 7.09 - 18.75 |
| Beta | undefined |
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used t...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 157
Stock Exchange NASDAQ
Ticker Symbol ITOS
Analyst Forecast
According to 3 analyst ratings, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 172.55% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 months ago ·
Source
-27.54%
iTeos Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
4 months ago ·
Source
+10.13%
iTeos Therapeutics shares are trading higher after the company announced the oral presentation of Phase 2 GALAXIES Lung-201 interim data at the European Society for Medical Oncology Congress 2024
